| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sinusitis | 61 | 2023 | 161 | 13.880 |
Why?
|
| Rhinitis | 55 | 2023 | 143 | 12.070 |
Why?
|
| Endoscopy | 71 | 2023 | 182 | 11.420 |
Why?
|
| Paranasal Sinuses | 30 | 2022 | 62 | 7.830 |
Why?
|
| Paranasal Sinus Neoplasms | 30 | 2022 | 63 | 6.170 |
Why?
|
| Nose Neoplasms | 13 | 2022 | 40 | 3.910 |
Why?
|
| Nasal Polyps | 19 | 2023 | 54 | 3.900 |
Why?
|
| Skull Base Neoplasms | 11 | 2015 | 19 | 3.250 |
Why?
|
| Skull Base | 15 | 2023 | 33 | 3.210 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 14 | 2019 | 29 | 3.190 |
Why?
|
| Chronic Disease | 51 | 2023 | 441 | 3.130 |
Why?
|
| Tomography, X-Ray Computed | 39 | 2022 | 730 | 2.980 |
Why?
|
| Papilloma, Inverted | 12 | 2015 | 15 | 2.830 |
Why?
|
| Middle Aged | 98 | 2023 | 9250 | 2.820 |
Why?
|
| Humans | 172 | 2023 | 28395 | 2.540 |
Why?
|
| Adult | 87 | 2023 | 8097 | 2.440 |
Why?
|
| Male | 111 | 2021 | 15269 | 2.410 |
Why?
|
| Female | 113 | 2022 | 15704 | 2.350 |
Why?
|
| Nose | 8 | 2020 | 36 | 2.260 |
Why?
|
| Retrospective Studies | 66 | 2023 | 3609 | 2.200 |
Why?
|
| Paranasal Sinus Diseases | 12 | 2010 | 13 | 2.120 |
Why?
|
| Otolaryngology | 8 | 2021 | 29 | 2.000 |
Why?
|
| Frontal Sinus | 9 | 2012 | 13 | 1.790 |
Why?
|
| Aged | 63 | 2023 | 9256 | 1.710 |
Why?
|
| Cerebrospinal Fluid Rhinorrhea | 7 | 2023 | 15 | 1.620 |
Why?
|
| Young Adult | 21 | 2020 | 2069 | 1.460 |
Why?
|
| Asthma | 6 | 2018 | 162 | 1.440 |
Why?
|
| Minimally Invasive Surgical Procedures | 8 | 2017 | 318 | 1.420 |
Why?
|
| Adolescent | 26 | 2020 | 2307 | 1.380 |
Why?
|
| Wound Healing | 3 | 2020 | 159 | 1.310 |
Why?
|
| Rhinitis, Allergic | 3 | 2021 | 16 | 1.290 |
Why?
|
| Treatment Outcome | 38 | 2023 | 3615 | 1.260 |
Why?
|
| Pseudomonas aeruginosa | 5 | 2018 | 64 | 1.260 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2015 | 177 | 1.260 |
Why?
|
| Surgery, Computer-Assisted | 9 | 2012 | 51 | 1.210 |
Why?
|
| Neuroendoscopy | 4 | 2020 | 8 | 1.200 |
Why?
|
| Telemedicine | 2 | 2020 | 119 | 1.190 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2023 | 206 | 1.190 |
Why?
|
| Nasal Cavity | 10 | 2020 | 32 | 1.160 |
Why?
|
| Aged, 80 and over | 31 | 2020 | 4851 | 1.150 |
Why?
|
| Staphylococcal Infections | 5 | 2018 | 158 | 1.150 |
Why?
|
| Follow-Up Studies | 23 | 2020 | 1858 | 1.140 |
Why?
|
| Ethmoid Sinus | 6 | 2017 | 10 | 1.130 |
Why?
|
| Betacoronavirus | 4 | 2020 | 77 | 1.110 |
Why?
|
| Pseudomonas Infections | 4 | 2015 | 50 | 1.110 |
Why?
|
| Quality of Life | 11 | 2022 | 658 | 1.090 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2020 | 122 | 1.080 |
Why?
|
| Coronavirus Infections | 4 | 2020 | 90 | 1.060 |
Why?
|
| Pneumonia, Viral | 4 | 2020 | 94 | 1.050 |
Why?
|
| Eosinophils | 5 | 2022 | 47 | 1.050 |
Why?
|
| Microbiota | 5 | 2020 | 104 | 1.030 |
Why?
|
| Epistaxis | 2 | 2020 | 9 | 1.030 |
Why?
|
| Disease Management | 2 | 2020 | 114 | 1.020 |
Why?
|
| Postoperative Complications | 8 | 2018 | 931 | 1.020 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 4 | 2020 | 11 | 0.980 |
Why?
|
| Nasal Septum | 4 | 2022 | 10 | 0.970 |
Why?
|
| Prospective Studies | 16 | 2022 | 1804 | 0.960 |
Why?
|
| Anti-Bacterial Agents | 6 | 2015 | 378 | 0.950 |
Why?
|
| Smoking | 4 | 2020 | 176 | 0.940 |
Why?
|
| Sphenoid Sinus | 9 | 2010 | 14 | 0.920 |
Why?
|
| Pandemics | 5 | 2020 | 260 | 0.860 |
Why?
|
| Catheterization | 3 | 2013 | 45 | 0.850 |
Why?
|
| Catheters | 2 | 2013 | 17 | 0.830 |
Why?
|
| Rhinitis, Allergic, Perennial | 4 | 2011 | 4 | 0.830 |
Why?
|
| Nasal Mucosa | 3 | 2019 | 13 | 0.820 |
Why?
|
| Nose Diseases | 4 | 2013 | 7 | 0.810 |
Why?
|
| Pituitary Neoplasms | 3 | 2020 | 16 | 0.780 |
Why?
|
| Prognosis | 13 | 2020 | 825 | 0.770 |
Why?
|
| Postoperative Care | 3 | 2020 | 139 | 0.770 |
Why?
|
| Fibrous Dysplasia of Bone | 2 | 2011 | 3 | 0.760 |
Why?
|
| Monitoring, Intraoperative | 4 | 2010 | 37 | 0.750 |
Why?
|
| Fluorescein | 2 | 2011 | 2 | 0.730 |
Why?
|
| Gram-Negative Bacterial Infections | 2 | 2012 | 24 | 0.730 |
Why?
|
| Neutrophils | 2 | 2018 | 110 | 0.730 |
Why?
|
| Fluorescent Dyes | 2 | 2011 | 38 | 0.720 |
Why?
|
| Dilatation | 3 | 2019 | 10 | 0.720 |
Why?
|
| Operating Rooms | 1 | 2020 | 15 | 0.710 |
Why?
|
| Surgical Flaps | 3 | 2020 | 51 | 0.710 |
Why?
|
| Hemostatic Techniques | 1 | 2020 | 7 | 0.710 |
Why?
|
| Ambulatory Care | 2 | 2020 | 74 | 0.700 |
Why?
|
| Otorhinolaryngologic Diseases | 1 | 2020 | 8 | 0.690 |
Why?
|
| Airway Management | 1 | 2020 | 15 | 0.690 |
Why?
|
| Urban Health Services | 1 | 2020 | 14 | 0.690 |
Why?
|
| Sleep Apnea, Obstructive | 2 | 2018 | 64 | 0.690 |
Why?
|
| Mucocele | 4 | 2008 | 4 | 0.680 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 23 | 0.680 |
Why?
|
| Turbinates | 3 | 2009 | 4 | 0.680 |
Why?
|
| Sella Turcica | 1 | 2019 | 3 | 0.670 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2018 | 80 | 0.670 |
Why?
|
| Neoplasm Staging | 11 | 2020 | 371 | 0.670 |
Why?
|
| Surgical Wound | 1 | 2019 | 9 | 0.660 |
Why?
|
| Eosinophilia | 5 | 2019 | 37 | 0.660 |
Why?
|
| Prednisone | 2 | 2018 | 65 | 0.630 |
Why?
|
| Magnetic Resonance Imaging | 16 | 2015 | 1143 | 0.630 |
Why?
|
| Rhinoplasty | 3 | 2022 | 14 | 0.630 |
Why?
|
| Bacteroidetes | 1 | 2018 | 3 | 0.620 |
Why?
|
| Firmicutes | 1 | 2018 | 6 | 0.620 |
Why?
|
| Severity of Illness Index | 10 | 2021 | 985 | 0.620 |
Why?
|
| United States | 11 | 2020 | 2196 | 0.620 |
Why?
|
| Mucormycosis | 2 | 2017 | 9 | 0.610 |
Why?
|
| Physicians | 1 | 2020 | 123 | 0.610 |
Why?
|
| Melanoma | 3 | 2019 | 60 | 0.600 |
Why?
|
| Nocturnal Myoclonus Syndrome | 1 | 2018 | 2 | 0.600 |
Why?
|
| Inflammation | 4 | 2023 | 284 | 0.600 |
Why?
|
| Eustachian Tube | 2 | 2019 | 4 | 0.600 |
Why?
|
| Diagnostic Errors | 1 | 2018 | 30 | 0.590 |
Why?
|
| Polysomnography | 1 | 2018 | 85 | 0.590 |
Why?
|
| Child | 12 | 2022 | 1421 | 0.580 |
Why?
|
| Orbit | 2 | 2015 | 2 | 0.570 |
Why?
|
| Staphylococcus aureus | 5 | 2018 | 68 | 0.570 |
Why?
|
| Surveys and Questionnaires | 7 | 2020 | 1215 | 0.560 |
Why?
|
| Pituitary Gland | 1 | 2017 | 13 | 0.560 |
Why?
|
| Invasive Fungal Infections | 1 | 2017 | 5 | 0.550 |
Why?
|
| Radiation Injuries | 1 | 2017 | 32 | 0.550 |
Why?
|
| Aspergillosis | 1 | 2017 | 11 | 0.550 |
Why?
|
| Frozen Sections | 1 | 2017 | 13 | 0.550 |
Why?
|
| Encephalocele | 3 | 2023 | 24 | 0.550 |
Why?
|
| Aerosols | 2 | 2020 | 23 | 0.540 |
Why?
|
| Fibroma, Ossifying | 3 | 2018 | 5 | 0.530 |
Why?
|
| Rhinomanometry | 3 | 2010 | 3 | 0.530 |
Why?
|
| Postoperative Period | 4 | 2018 | 331 | 0.520 |
Why?
|
| Gastroesophageal Reflux | 1 | 2016 | 27 | 0.520 |
Why?
|
| Administration, Intranasal | 5 | 2011 | 27 | 0.510 |
Why?
|
| Adenocarcinoma | 2 | 2019 | 147 | 0.500 |
Why?
|
| Nebulizers and Vaporizers | 4 | 2011 | 25 | 0.500 |
Why?
|
| Dacryocystorhinostomy | 1 | 2015 | 1 | 0.500 |
Why?
|
| Carcinoma | 3 | 2010 | 69 | 0.480 |
Why?
|
| Frontal Sinusitis | 2 | 2012 | 3 | 0.480 |
Why?
|
| Anti-Infective Agents | 1 | 2015 | 36 | 0.470 |
Why?
|
| Antifungal Agents | 2 | 2013 | 43 | 0.470 |
Why?
|
| Tertiary Care Centers | 5 | 2020 | 67 | 0.460 |
Why?
|
| Endoscopes | 2 | 2011 | 9 | 0.450 |
Why?
|
| Disease Progression | 6 | 2018 | 717 | 0.450 |
Why?
|
| Stenotrophomonas maltophilia | 2 | 2012 | 2 | 0.450 |
Why?
|
| Pituitary Diseases | 1 | 2013 | 3 | 0.450 |
Why?
|
| Otitis Externa | 1 | 2013 | 1 | 0.440 |
Why?
|
| Osteomyelitis | 1 | 2013 | 20 | 0.440 |
Why?
|
| Diabetes Complications | 1 | 2013 | 59 | 0.430 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2015 | 116 | 0.430 |
Why?
|
| Allergens | 3 | 2019 | 16 | 0.430 |
Why?
|
| Osteoma | 2 | 2018 | 5 | 0.430 |
Why?
|
| Clinical Competence | 4 | 2020 | 249 | 0.430 |
Why?
|
| Drainage | 2 | 2015 | 49 | 0.420 |
Why?
|
| Hospitalization | 1 | 2016 | 323 | 0.420 |
Why?
|
| Granuloma, Foreign-Body | 1 | 2012 | 2 | 0.410 |
Why?
|
| Sarcoidosis | 1 | 2013 | 14 | 0.410 |
Why?
|
| Granulomatosis with Polyangiitis | 2 | 2009 | 11 | 0.410 |
Why?
|
| Cholesterol | 1 | 2012 | 64 | 0.400 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2006 | 169 | 0.390 |
Why?
|
| Algorithms | 2 | 2011 | 377 | 0.390 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2012 | 46 | 0.390 |
Why?
|
| Dura Mater | 1 | 2012 | 16 | 0.390 |
Why?
|
| Evidence-Based Practice | 1 | 2012 | 85 | 0.390 |
Why?
|
| Cadaver | 5 | 2013 | 376 | 0.390 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2012 | 53 | 0.380 |
Why?
|
| Clinical Trials as Topic | 2 | 2012 | 239 | 0.380 |
Why?
|
| Maxillary Sinus Neoplasms | 2 | 2010 | 7 | 0.380 |
Why?
|
| Odds Ratio | 3 | 2018 | 268 | 0.370 |
Why?
|
| Myxosarcoma | 1 | 2011 | 3 | 0.370 |
Why?
|
| Fibrosarcoma | 1 | 2011 | 9 | 0.360 |
Why?
|
| Acetazolamide | 1 | 2010 | 3 | 0.360 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2010 | 6 | 0.360 |
Why?
|
| Cranial Fossa, Posterior | 2 | 2010 | 7 | 0.360 |
Why?
|
| Mycoses | 1 | 2011 | 23 | 0.360 |
Why?
|
| Air Pollutants | 2 | 2021 | 11 | 0.360 |
Why?
|
| Sodium Chloride | 1 | 2011 | 36 | 0.360 |
Why?
|
| Fellowships and Scholarships | 1 | 2011 | 44 | 0.360 |
Why?
|
| Cohort Studies | 6 | 2020 | 1926 | 0.360 |
Why?
|
| Rhinitis, Allergic, Seasonal | 1 | 2010 | 5 | 0.350 |
Why?
|
| Education, Medical, Graduate | 1 | 2011 | 77 | 0.340 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2020 | 29 | 0.340 |
Why?
|
| Arteries | 1 | 2009 | 16 | 0.330 |
Why?
|
| Anastomosis, Surgical | 1 | 2009 | 30 | 0.330 |
Why?
|
| Simulation Training | 2 | 2020 | 38 | 0.330 |
Why?
|
| Survival Analysis | 4 | 2015 | 267 | 0.330 |
Why?
|
| Cerebrospinal Fluid Leak | 3 | 2023 | 21 | 0.330 |
Why?
|
| Age Factors | 4 | 2020 | 781 | 0.330 |
Why?
|
| Disease-Free Survival | 5 | 2015 | 177 | 0.320 |
Why?
|
| Pharmacists | 2 | 2019 | 19 | 0.310 |
Why?
|
| Bone Resorption | 1 | 2009 | 85 | 0.310 |
Why?
|
| Meningocele | 1 | 2008 | 4 | 0.310 |
Why?
|
| Intracranial Hypertension | 2 | 2023 | 15 | 0.300 |
Why?
|
| Radioallergosorbent Test | 1 | 2008 | 1 | 0.300 |
Why?
|
| Neoplasm Metastasis | 3 | 2015 | 102 | 0.300 |
Why?
|
| Skin Tests | 1 | 2008 | 8 | 0.300 |
Why?
|
| Poaceae | 1 | 2008 | 4 | 0.300 |
Why?
|
| Reproducibility of Results | 6 | 2021 | 733 | 0.300 |
Why?
|
| Carotid Artery, Internal | 2 | 2005 | 8 | 0.290 |
Why?
|
| Reoperation | 5 | 2019 | 917 | 0.290 |
Why?
|
| Immunosuppressive Agents | 2 | 2019 | 140 | 0.290 |
Why?
|
| Evidence-Based Medicine | 4 | 2016 | 196 | 0.290 |
Why?
|
| Survival Rate | 5 | 2020 | 356 | 0.290 |
Why?
|
| Comorbidity | 3 | 2018 | 500 | 0.290 |
Why?
|
| Hypersensitivity | 1 | 2008 | 48 | 0.290 |
Why?
|
| Tracheostomy | 3 | 2020 | 27 | 0.280 |
Why?
|
| Recurrence | 4 | 2018 | 322 | 0.280 |
Why?
|
| Biopsy | 3 | 2018 | 220 | 0.280 |
Why?
|
| Meningioma | 2 | 2005 | 12 | 0.260 |
Why?
|
| Frontal Bone | 1 | 2005 | 1 | 0.250 |
Why?
|
| Trephining | 1 | 2005 | 1 | 0.250 |
Why?
|
| Orbit Evisceration | 1 | 2005 | 1 | 0.250 |
Why?
|
| Sphenoid Sinusitis | 1 | 2005 | 1 | 0.240 |
Why?
|
| Hypophysectomy | 1 | 2005 | 3 | 0.240 |
Why?
|
| Nasal Surgical Procedures | 2 | 2017 | 10 | 0.240 |
Why?
|
| Optic Nerve | 1 | 2004 | 5 | 0.240 |
Why?
|
| Illinois | 4 | 2019 | 246 | 0.240 |
Why?
|
| Air Pollution | 2 | 2021 | 16 | 0.230 |
Why?
|
| Diagnosis, Differential | 4 | 2018 | 372 | 0.220 |
Why?
|
| Particulate Matter | 2 | 2021 | 20 | 0.220 |
Why?
|
| Preoperative Period | 3 | 2019 | 81 | 0.220 |
Why?
|
| Health Surveys | 2 | 2015 | 88 | 0.220 |
Why?
|
| Professional Role | 2 | 2021 | 36 | 0.220 |
Why?
|
| Societies, Medical | 2 | 2015 | 154 | 0.210 |
Why?
|
| Residence Characteristics | 2 | 2017 | 214 | 0.210 |
Why?
|
| Case-Control Studies | 4 | 2023 | 593 | 0.200 |
Why?
|
| Sensitivity and Specificity | 3 | 2017 | 517 | 0.200 |
Why?
|
| Cochlear Nerve | 1 | 2002 | 1 | 0.200 |
Why?
|
| Cerebellar Neoplasms | 1 | 2002 | 5 | 0.200 |
Why?
|
| Cerebellopontine Angle | 1 | 2002 | 4 | 0.200 |
Why?
|
| Nasal Cartilages | 1 | 2022 | 3 | 0.200 |
Why?
|
| Confidence Intervals | 2 | 2013 | 95 | 0.200 |
Why?
|
| Leukocyte Count | 2 | 2019 | 66 | 0.200 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2020 | 55 | 0.200 |
Why?
|
| Facial Nerve | 1 | 2002 | 13 | 0.200 |
Why?
|
| Risk Factors | 5 | 2021 | 2408 | 0.200 |
Why?
|
| Child, Preschool | 4 | 2017 | 689 | 0.200 |
Why?
|
| Biopsy, Needle | 3 | 2012 | 108 | 0.190 |
Why?
|
| Time Factors | 5 | 2021 | 1490 | 0.190 |
Why?
|
| Preoperative Care | 3 | 2020 | 125 | 0.190 |
Why?
|
| Prevalence | 2 | 2016 | 467 | 0.190 |
Why?
|
| Leiomyosarcoma | 1 | 2001 | 21 | 0.190 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 137 | 0.190 |
Why?
|
| Radiology | 1 | 2021 | 16 | 0.190 |
Why?
|
| Immunohistochemistry | 3 | 2012 | 362 | 0.190 |
Why?
|
| Papilloma | 1 | 2001 | 3 | 0.190 |
Why?
|
| Software | 3 | 2008 | 65 | 0.190 |
Why?
|
| Biodiversity | 2 | 2018 | 35 | 0.190 |
Why?
|
| Combined Modality Therapy | 5 | 2019 | 307 | 0.190 |
Why?
|
| Hemoptysis | 1 | 2001 | 7 | 0.190 |
Why?
|
| Feasibility Studies | 2 | 2013 | 231 | 0.180 |
Why?
|
| Corynebacterium | 1 | 2020 | 2 | 0.180 |
Why?
|
| Laryngeal Neoplasms | 1 | 2001 | 32 | 0.180 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2001 | 42 | 0.180 |
Why?
|
| Morbidity | 2 | 2013 | 58 | 0.180 |
Why?
|
| Fibrosis | 2 | 2018 | 30 | 0.180 |
Why?
|
| Esophageal Neoplasms | 1 | 2001 | 54 | 0.180 |
Why?
|
| Nasopharynx | 1 | 2020 | 5 | 0.170 |
Why?
|
| Laryngopharyngeal Reflux | 1 | 2020 | 2 | 0.170 |
Why?
|
| Personnel, Hospital | 1 | 2020 | 16 | 0.170 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 18 | 0.170 |
Why?
|
| Middle Ear Ventilation | 1 | 2000 | 1 | 0.170 |
Why?
|
| Otitis Media with Effusion | 1 | 2000 | 1 | 0.170 |
Why?
|
| Hearing Loss, Conductive | 1 | 2000 | 3 | 0.170 |
Why?
|
| Rhinometry, Acoustic | 2 | 2010 | 2 | 0.170 |
Why?
|
| Cryosurgery | 1 | 2020 | 24 | 0.170 |
Why?
|
| Emergencies | 1 | 2020 | 36 | 0.170 |
Why?
|
| Genomics | 1 | 2020 | 57 | 0.170 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2020 | 5 | 0.170 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2021 | 81 | 0.170 |
Why?
|
| Point-of-Care Testing | 1 | 2020 | 30 | 0.170 |
Why?
|
| Consensus | 2 | 2021 | 98 | 0.170 |
Why?
|
| Surgeons | 1 | 2021 | 89 | 0.170 |
Why?
|
| Risk Assessment | 3 | 2012 | 676 | 0.170 |
Why?
|
| Asthma, Aspirin-Induced | 1 | 2019 | 1 | 0.160 |
Why?
|
| Drug Hypersensitivity | 1 | 2019 | 6 | 0.160 |
Why?
|
| Internet | 1 | 2020 | 98 | 0.160 |
Why?
|
| Mandibular Neoplasms | 1 | 1999 | 2 | 0.160 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 1999 | 4 | 0.160 |
Why?
|
| Desensitization, Immunologic | 1 | 2019 | 4 | 0.160 |
Why?
|
| Ear Diseases | 1 | 2019 | 3 | 0.160 |
Why?
|
| Tympanic Membrane | 1 | 1999 | 4 | 0.160 |
Why?
|
| Voice Quality | 1 | 2019 | 9 | 0.160 |
Why?
|
| Adenoma | 1 | 2020 | 60 | 0.160 |
Why?
|
| Mitomycin | 1 | 1999 | 9 | 0.160 |
Why?
|
| Skin | 1 | 2020 | 116 | 0.160 |
Why?
|
| Chondrosarcoma | 1 | 1999 | 33 | 0.160 |
Why?
|
| Social Discrimination | 1 | 2019 | 7 | 0.160 |
Why?
|
| Temporomandibular Joint | 1 | 1999 | 18 | 0.160 |
Why?
|
| Acute Disease | 2 | 2017 | 208 | 0.160 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2019 | 34 | 0.160 |
Why?
|
| Professional-Patient Relations | 1 | 2019 | 28 | 0.160 |
Why?
|
| Aspirin | 2 | 2019 | 84 | 0.160 |
Why?
|
| Community Pharmacy Services | 1 | 2018 | 1 | 0.160 |
Why?
|
| Maxillary Diseases | 1 | 2018 | 4 | 0.160 |
Why?
|
| Insurance Coverage | 1 | 2019 | 16 | 0.160 |
Why?
|
| Metaplasia | 1 | 2018 | 7 | 0.160 |
Why?
|
| Phenotype | 2 | 2019 | 310 | 0.160 |
Why?
|
| Transgender Persons | 1 | 2019 | 21 | 0.160 |
Why?
|
| Glucocorticoids | 2 | 2010 | 70 | 0.160 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2019 | 192 | 0.160 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 94 | 0.150 |
Why?
|
| Laryngoscopy | 2 | 2013 | 18 | 0.150 |
Why?
|
| Mucous Membrane | 2 | 2017 | 29 | 0.150 |
Why?
|
| Patient Care | 1 | 2018 | 31 | 0.150 |
Why?
|
| Osteoblastoma | 1 | 2018 | 3 | 0.150 |
Why?
|
| Headache | 1 | 1998 | 34 | 0.150 |
Why?
|
| Patient-Centered Care | 1 | 2018 | 59 | 0.150 |
Why?
|
| Neurosurgical Procedures | 2 | 2010 | 127 | 0.150 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2017 | 7 | 0.150 |
Why?
|
| Internship and Residency | 1 | 2021 | 219 | 0.140 |
Why?
|
| Neoplasms, Second Primary | 1 | 2018 | 40 | 0.140 |
Why?
|
| Basement Membrane | 1 | 2017 | 11 | 0.140 |
Why?
|
| Nasal Obstruction | 2 | 2011 | 4 | 0.140 |
Why?
|
| Mucor | 1 | 2017 | 5 | 0.140 |
Why?
|
| Referral and Consultation | 1 | 2018 | 91 | 0.140 |
Why?
|
| Aspergillus | 1 | 2017 | 7 | 0.140 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2011 | 199 | 0.140 |
Why?
|
| Edema | 1 | 2017 | 25 | 0.140 |
Why?
|
| Radiation Dosage | 2 | 2015 | 39 | 0.140 |
Why?
|
| Poverty | 1 | 2017 | 100 | 0.140 |
Why?
|
| Radiography | 4 | 2011 | 639 | 0.140 |
Why?
|
| Animals | 4 | 2013 | 3780 | 0.140 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 46 | 0.140 |
Why?
|
| Pilot Projects | 3 | 2018 | 439 | 0.140 |
Why?
|
| Craniotomy | 2 | 2006 | 21 | 0.130 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 506 | 0.130 |
Why?
|
| Population Surveillance | 1 | 2016 | 110 | 0.120 |
Why?
|
| Body Mass Index | 1 | 2018 | 465 | 0.120 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 932 | 0.120 |
Why?
|
| Decision Making | 1 | 2017 | 226 | 0.120 |
Why?
|
| Biomarkers | 1 | 2017 | 596 | 0.110 |
Why?
|
| Ohio | 1 | 2013 | 7 | 0.110 |
Why?
|
| Intraoperative Period | 2 | 2011 | 27 | 0.110 |
Why?
|
| Ear, Middle | 1 | 2013 | 8 | 0.110 |
Why?
|
| Statistics, Nonparametric | 2 | 2010 | 128 | 0.110 |
Why?
|
| Data Collection | 1 | 2013 | 98 | 0.110 |
Why?
|
| Debridement | 1 | 2013 | 102 | 0.110 |
Why?
|
| Cell Culture Techniques | 1 | 2013 | 32 | 0.110 |
Why?
|
| Suction | 1 | 2013 | 40 | 0.100 |
Why?
|
| Specimen Handling | 1 | 2013 | 44 | 0.100 |
Why?
|
| Equipment Design | 2 | 2011 | 152 | 0.100 |
Why?
|
| Technology Transfer | 1 | 2012 | 3 | 0.100 |
Why?
|
| Patient Selection | 2 | 2020 | 206 | 0.100 |
Why?
|
| Neurosurgery | 1 | 2013 | 31 | 0.100 |
Why?
|
| Drug Delivery Systems | 1 | 2012 | 31 | 0.100 |
Why?
|
| Radionuclide Imaging | 1 | 2012 | 43 | 0.100 |
Why?
|
| Cholesteatoma | 1 | 2011 | 1 | 0.100 |
Why?
|
| Granuloma | 1 | 2011 | 15 | 0.100 |
Why?
|
| Mometasone Furoate | 2 | 2022 | 8 | 0.100 |
Why?
|
| Double-Blind Method | 1 | 2013 | 432 | 0.100 |
Why?
|
| Itraconazole | 1 | 2011 | 4 | 0.100 |
Why?
|
| Ketoconazole | 1 | 2011 | 5 | 0.090 |
Why?
|
| Administration, Oral | 1 | 2011 | 111 | 0.090 |
Why?
|
| Video-Assisted Surgery | 1 | 2011 | 2 | 0.090 |
Why?
|
| Positron-Emission Tomography | 1 | 2011 | 89 | 0.090 |
Why?
|
| Workload | 1 | 2011 | 33 | 0.090 |
Why?
|
| Career Choice | 1 | 2011 | 30 | 0.090 |
Why?
|
| Sex Factors | 1 | 2012 | 475 | 0.090 |
Why?
|
| Cerebrospinal Fluid Pressure | 1 | 2010 | 2 | 0.090 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2011 | 52 | 0.090 |
Why?
|
| Empty Sella Syndrome | 1 | 2010 | 3 | 0.090 |
Why?
|
| Intraoperative Care | 1 | 2011 | 43 | 0.090 |
Why?
|
| Injections, Spinal | 1 | 2010 | 32 | 0.090 |
Why?
|
| Bone Neoplasms | 1 | 2012 | 120 | 0.090 |
Why?
|
| Oxymetazoline | 1 | 2010 | 1 | 0.090 |
Why?
|
| Histamine | 1 | 2010 | 8 | 0.090 |
Why?
|
| Dermatophagoides farinae | 1 | 2010 | 1 | 0.090 |
Why?
|
| Antigens, Dermatophagoides | 1 | 2010 | 2 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 1 | 2010 | 89 | 0.090 |
Why?
|
| Laser Therapy | 2 | 2001 | 12 | 0.090 |
Why?
|
| Suppuration | 1 | 2010 | 1 | 0.090 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 492 | 0.090 |
Why?
|
| Chemoradiotherapy | 1 | 2010 | 61 | 0.090 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2010 | 3 | 0.090 |
Why?
|
| Fluoroquinolones | 1 | 2010 | 15 | 0.090 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2010 | 20 | 0.090 |
Why?
|
| Drug Resistance | 1 | 2010 | 47 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 179 | 0.090 |
Why?
|
| Chordoma | 1 | 2010 | 9 | 0.090 |
Why?
|
| Monitoring, Physiologic | 1 | 2010 | 76 | 0.090 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 81 | 0.080 |
Why?
|
| Tyrosine | 2 | 2007 | 25 | 0.080 |
Why?
|
| Hypertrophy | 1 | 2009 | 24 | 0.080 |
Why?
|
| Neoplasm Grading | 2 | 2020 | 52 | 0.080 |
Why?
|
| Osteogenesis | 1 | 2009 | 110 | 0.080 |
Why?
|
| Visual Acuity | 1 | 2008 | 39 | 0.080 |
Why?
|
| Delphi Technique | 2 | 2019 | 27 | 0.080 |
Why?
|
| Budesonide | 1 | 2008 | 3 | 0.080 |
Why?
|
| Ambrosia | 1 | 2008 | 1 | 0.080 |
Why?
|
| Phleum | 1 | 2008 | 1 | 0.080 |
Why?
|
| Ethmoid Bone | 1 | 2008 | 2 | 0.080 |
Why?
|
| Back | 1 | 2008 | 2 | 0.080 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2008 | 29 | 0.070 |
Why?
|
| Papillomavirus Infections | 1 | 2007 | 19 | 0.070 |
Why?
|
| Arm | 1 | 2008 | 84 | 0.070 |
Why?
|
| Petrous Bone | 2 | 2021 | 5 | 0.070 |
Why?
|
| Cystic Fibrosis | 1 | 2007 | 10 | 0.070 |
Why?
|
| Chicago | 2 | 2020 | 939 | 0.070 |
Why?
|
| Histoplasmosis | 1 | 2006 | 8 | 0.070 |
Why?
|
| Polyps | 1 | 2006 | 3 | 0.070 |
Why?
|
| Physicians' Offices | 1 | 2006 | 7 | 0.070 |
Why?
|
| Allergy and Immunology | 1 | 2006 | 5 | 0.070 |
Why?
|
| Mupirocin | 1 | 2006 | 17 | 0.070 |
Why?
|
| Radiographic Image Enhancement | 1 | 2006 | 27 | 0.070 |
Why?
|
| Methicillin Resistance | 1 | 2006 | 25 | 0.070 |
Why?
|
| Therapeutic Irrigation | 1 | 2006 | 56 | 0.060 |
Why?
|
| Intraoperative Complications | 1 | 2006 | 67 | 0.060 |
Why?
|
| Physical Examination | 1 | 2006 | 118 | 0.060 |
Why?
|
| Posture | 1 | 2005 | 66 | 0.060 |
Why?
|
| Dexamethasone | 1 | 2005 | 35 | 0.060 |
Why?
|
| Eyelids | 1 | 2005 | 1 | 0.060 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2005 | 3 | 0.060 |
Why?
|
| Signal Transduction | 1 | 2007 | 447 | 0.060 |
Why?
|
| Administration, Topical | 2 | 2008 | 16 | 0.060 |
Why?
|
| Gram-Positive Bacteria | 1 | 2005 | 13 | 0.060 |
Why?
|
| Equipment Contamination | 1 | 2005 | 24 | 0.060 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2004 | 17 | 0.060 |
Why?
|
| Evaluation Studies as Topic | 2 | 2005 | 37 | 0.060 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2022 | 34 | 0.050 |
Why?
|
| Facial Nerve Diseases | 1 | 2002 | 3 | 0.050 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2002 | 13 | 0.050 |
Why?
|
| Nasal Lavage | 1 | 2021 | 4 | 0.050 |
Why?
|
| Pituitary-Adrenal System | 1 | 2021 | 13 | 0.050 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2021 | 23 | 0.050 |
Why?
|
| Cerebrospinal Fluid Otorrhea | 1 | 2021 | 3 | 0.050 |
Why?
|
| Hydrocortisone | 1 | 2021 | 40 | 0.050 |
Why?
|
| Taste Disorders | 1 | 2021 | 4 | 0.050 |
Why?
|
| Esophagoscopy | 1 | 2001 | 15 | 0.050 |
Why?
|
| Hospitals, Teaching | 1 | 2021 | 31 | 0.050 |
Why?
|
| Respiratory Tract Infections | 1 | 2001 | 27 | 0.050 |
Why?
|
| Bronchoscopy | 1 | 2001 | 34 | 0.050 |
Why?
|
| Environmental Exposure | 1 | 2021 | 17 | 0.050 |
Why?
|
| Logistic Models | 1 | 2022 | 395 | 0.050 |
Why?
|
| Observer Variation | 1 | 2021 | 102 | 0.040 |
Why?
|
| Particle Size | 1 | 2020 | 53 | 0.040 |
Why?
|
| Olfaction Disorders | 1 | 2021 | 49 | 0.040 |
Why?
|
| DNA, Ribosomal | 1 | 2020 | 5 | 0.040 |
Why?
|
| Surgery Department, Hospital | 1 | 2020 | 4 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2020 | 44 | 0.040 |
Why?
|
| Biometry | 1 | 2020 | 7 | 0.040 |
Why?
|
| Education, Nursing, Continuing | 1 | 2020 | 19 | 0.040 |
Why?
|
| Inservice Training | 1 | 2020 | 28 | 0.040 |
Why?
|
| Audiometry, Pure-Tone | 1 | 2000 | 13 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2020 | 60 | 0.040 |
Why?
|
| Auditory Threshold | 1 | 2000 | 24 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2020 | 31 | 0.040 |
Why?
|
| Patient Care Planning | 1 | 2020 | 52 | 0.040 |
Why?
|
| Interleukin-5 | 1 | 2019 | 5 | 0.040 |
Why?
|
| Pharmaceutical Services | 1 | 2019 | 2 | 0.040 |
Why?
|
| Culturally Competent Care | 1 | 2019 | 11 | 0.040 |
Why?
|
| Infant | 1 | 2001 | 587 | 0.040 |
Why?
|
| Mass Screening | 1 | 2020 | 182 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1999 | 341 | 0.040 |
Why?
|
| Program Development | 1 | 2018 | 64 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 111 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2018 | 75 | 0.040 |
Why?
|
| Self Report | 1 | 2019 | 221 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2018 | 137 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2019 | 183 | 0.040 |
Why?
|
| SEER Program | 1 | 2018 | 41 | 0.040 |
Why?
|
| Age Distribution | 1 | 2018 | 89 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2018 | 82 | 0.040 |
Why?
|
| Rats | 1 | 1999 | 678 | 0.040 |
Why?
|
| Income | 1 | 2017 | 77 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2018 | 207 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2019 | 358 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 328 | 0.030 |
Why?
|
| Perioperative Care | 1 | 2015 | 45 | 0.030 |
Why?
|
| Probability | 2 | 2005 | 90 | 0.030 |
Why?
|
| Neck | 1 | 2011 | 26 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2011 | 90 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2011 | 70 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2008 | 33 | 0.020 |
Why?
|
| Neck Dissection | 1 | 2008 | 20 | 0.020 |
Why?
|
| DNA Probes, HPV | 1 | 2007 | 1 | 0.020 |
Why?
|
| Microdissection | 1 | 2007 | 1 | 0.020 |
Why?
|
| omega-N-Methylarginine | 1 | 2007 | 3 | 0.020 |
Why?
|
| STAT1 Transcription Factor | 1 | 2007 | 2 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2007 | 23 | 0.020 |
Why?
|
| Alphapapillomavirus | 1 | 2007 | 6 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 2007 | 19 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2007 | 57 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2007 | 51 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2007 | 65 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2008 | 163 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2007 | 72 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2007 | 81 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 120 | 0.020 |
Why?
|
| Surgery, Plastic | 1 | 2007 | 11 | 0.020 |
Why?
|
| Stereotaxic Techniques | 1 | 2006 | 14 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2007 | 284 | 0.020 |
Why?
|
| Electromagnetic Phenomena | 1 | 2006 | 1 | 0.020 |
Why?
|
| Surgical Equipment | 1 | 2006 | 2 | 0.020 |
Why?
|
| Phantoms, Imaging | 1 | 2006 | 39 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2006 | 21 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2006 | 38 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2006 | 47 | 0.020 |
Why?
|
| Subdural Effusion | 1 | 2005 | 6 | 0.020 |
Why?
|
| Titanium | 1 | 2006 | 181 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 166 | 0.020 |
Why?
|
| Bone Screws | 1 | 2006 | 146 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2005 | 269 | 0.020 |
Why?
|
| Colony Count, Microbial | 1 | 2005 | 18 | 0.020 |
Why?
|
| Sterilization | 1 | 2005 | 9 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 351 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2005 | 88 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2005 | 176 | 0.010 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2005 | 55 | 0.010 |
Why?
|
| Culture Techniques | 1 | 2004 | 17 | 0.010 |
Why?
|
| Materials Testing | 1 | 2005 | 136 | 0.010 |
Why?
|